Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Ryaltris Generic Name & Formulations
Legal Class
General Description
Pharmacological Class
How Supplied
Spray—29g (240 sprays)
Manufacturer
Generic Availability
NO
Mechanism of Action
Olopatadine is a histamine-1 (H1) receptor inhibitor. The antihistaminic activity of olopatadine has been documented in isolated tissues, animal models, and humans.
Mometasone furoate is a corticosteroid demonstrating potent anti-inflammatory activity. The precise mechanism of corticosteroid action on allergic rhinitis is not known. Corticosteroids have been shown to have a wide range of inhibitory effects on multiple cell types (eg, mast cells, eosinophils, neutrophils, macrophages, and lymphocytes) and mediators (eg, histamine, eicosanoids, leukotrienes, and cytokines) involved in inflammation.
Ryaltris Indications
Indications
Seasonal allergic rhinitis.
Ryaltris Dosage and Administration
Adult
Use 2 sprays in each nostril twice daily.
Children
<12yrs: not established.
Ryaltris Contraindications
Not Applicable
Ryaltris Boxed Warnings
Not Applicable
Ryaltris Warnings/Precautions
Warnings/Precautions
Risk of epistaxis, nasal ulcerations, nasal septal perforations, impaired nasal wound healing, local Candida infections; monitor periodically. Recent nasal septal ulcers, nasal surgery, or nasal trauma: avoid until healing has occurred. Discontinue if Candida infections or hypersensitivity reactions occur. Monitor closely if change in vision or those with a history of increased intraocular pressure, glaucoma, and/or cataracts. Immunosuppression. Respiratory tract tuberculosis. Infections (eg, fungal, bacterial, viral, ocular herpes simplex). If exposed to measles or chickenpox, may need immunoglobulin or VZIG prophylactic therapy. Hypercorticism. Adrenal suppression. Monitor routinely for growth in children. Hepatic impairment. Pregnancy. Nursing mothers.
Ryaltris Pharmacokinetics
Distribution
Olopatadine: ~55% human serum protein bound. Mometasone furoate: 98-99% in vitro protein bound.
Elimination
Olopatadine: renal (~70%), fecal (~17%). Half-life: 9 hours (olopatadine); 18 hours (mometasone furoate).
Ryaltris Interactions
Interactions
Avoid concomitant alcohol or other CNS depressants. Caution with strong CYP3A4 inhibitors (eg, ketoconazole).
Ryaltris Adverse Reactions
Adverse Reactions
Dysgeusia, epistaxis, nasal discomfort; somnolence, impaired mental alertness.
Ryaltris Clinical Trials
See Literature
Ryaltris Note
Not Applicable
Ryaltris Patient Counseling
See Literature
